← Leaderboards
Scott Hammer
Beth Israel Deaconess Medical Center
$387,832
Attributed
$387,832
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$387,832 · 3
By mechanism
M01$387,832 · 3
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Mary Albrecht$387,832
- Bruce J Dezube$965,277
- David Ives$387,832
- Steven C. Schachter$10,007,385
- Susan L Greenspan$27,746,173
Others in their field
Top investigators on “Aids Therapy”
- Lawrence Corey · Fred Hutchinson Cancer Center$356,191,804
- Constance Ann Benson · University Of California, San Diego$277,003,036
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$262,875,323
- Barbara Driver · Westat, Inc.$205,980,213
- Sharon A Nachman · Johns Hopkins University$193,704,208
- Carol Nesel · Westat$188,148,170
Research focus
Aids TherapyClinical ResearchCombination ChemotherapyDrug Screening /EvaluationHiv InfectionsHuman SubjectHuman Therapy EvaluationAntiaids AgentAntiviral AgentsDrug Adverse EffectNucleoside AnalogVirus LoadOutcomes ResearchProtease InhibitorRitonavirReverse Transcriptase InhibitorsClinical Trial Phase I
Grant awards (12)
ACTG 372--VIRUS LOAD IN PATIENTS RECEIVING INDINAVIR IN COMBINATION$0
M01 · FY2002 · RR
ACTG 398: AMPRENAVIR COMBINATION THERAPY FOR HIV INFECTED SUBJECTS$0
M01 · FY2002 · RR
ACTG 372--VIRUS LOAD IN PATIENTS RECEIVING INDINAVIR IN COMBINATION$0
M01 · FY2001 · RR
ACTG 398: AMPRENAVIR COMBINATION THERAPY FOR HIV INFECTED SUBJECTS$0
M01 · FY2001 · RR
ABT 378/RITONAVIR IN COMBINATION W/ REVERSE TRANSCRIPTASE INHIBITORS$193,916
M01 · FY2000 · RR
ABT 378/RITONAVIR IN COMBINATION W/ REVERSE TRANSCRIPTASE INHIBITORS$193,916
M01 · FY2000 · RR
ACTG 398: AMPRENAVIR COMBINATION THERAPY FOR HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR
ACTG 372--VIRUS LOAD IN PATIENTS RECEIVING INDINAVIR IN COMBINATION$0
M01 · FY2000 · RR
ACTG 372--VIRUS LOAD IN PATIENTS RECEIVING INDINAVIR IN COMBINATION$0
M01 · FY2000 · RR
ACTG 398: AMPRENAVIR COMBINATION THERAPY FOR HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR
ACTG 372--VIRUS LOAD IN PATIENTS RECEIVING INDINAVIR IN COMBINATION$0
M01 · FY2000 · RR
ACTG 398: AMPRENAVIR COMBINATION THERAPY FOR HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR